Yarom N, et al. - A retrospective chart review of chemotherapy-treated patients with metastatic colorectal cancers (CRCs) with known KRAS status was done to assess the impact of KRAS status on the activity of various chemotherapeutic regimens. In 43% of 223 individuals with metastatic CRC who were treated at the Ottawa Hospital, KRAS mutations were identified. The baseline distribution of KRAS wild-type (WT) and mutant status was comparable. Regimens received incorporated single agents or combinations of two or three chemotherapies. When compared with those with mutant status, among those treated with capecitabine-based regimens, survival was longer for individuals with KRAS WT status. For individuals with WT status, the time to chemotherapy resistance was also significantly prolonged. A trend for progression-free survival did not attain statistical importance. Hence, individuals with KRAS WT tumors may profit more from capecitabine-based treatments in comparison with patients with mutant status. Additional study is required to reveal this data.